Application of dodecylmethylaminoethyl methacrylate (DMAMA) in preparation of medicine for inhibiting helicobacter pylori in oral cavity and stomach

Abstract

The invention belongs to the technical field of anti-helicobacter pylori treatment, and discloses application of DMAMA in preparation of a medicine for inhibiting helicobacter pylori in the oral cavity and the stomach. According to the invention, the minimum inhibitory concentration and the minimum bactericidal concentration of the medicine are determined through flat plate and bacterial suspension culture; the variation of bacterial quantities under the action of the medicine and the influence of the medicine on a bacterial toxicity level are determined; and cell safety detection is conducted. Aiming at the conditions that local drugs for effectively treating helicobacter pylori infection are lacked under existing conditions and the drug resistance rate of helicobacter pylori antibiotics is increased year by year, the pH sensitive characteristic of the DMAEM is combined for the first time, the DMAEM acts on the helicobacter pylori, and it is found that the DMAEM has a remarkable bactericidal effect on the helicobacter pylori and can effectively prevent and treat the helicobacter pylori infection. Meanwhile, the detection of the DMAEM has good biological safety. The DMAEM has relatively strong helicobacter pylori growth and proliferation resisting effects, so the adverse use of antibiotics is reduced, and the problems of antibiotic resistance and host flora disorder caused by antibiotic resistance are reduced.

Description

technical field [0001] The invention belongs to the technical field of anti-helicobacter pylori treatment, and in particular relates to the use of a tertiary amine monomer in the preparation of medicines for inhibiting oral and gastric helicobacter pylori. Background technique [0002] At present, Helicobacter pylori is a common infectious bacteria in humans, and its infection has become a global health problem. More than half of the people in the world are infected with Helicobacter pylori, and the infection rate in my country is 40-60%. Helicobacter pylori is a risk factor for many diseases such as chronic gastritis, gastric ulcer, gastric adenocarcinoma, and even mucosa-associated lymphoid tissue lymphoma. In 1994, the International Agency for Research on Cancer (IARC) of the World Health Organization listed Helicobacter pylori as a human I carcinogen. 67% to 80% of gastric ulcers and 95% of duodenal ulcers are caused by Helicobacter pylori, and about 39% of gastric canc...

AI Technical Summary

Problems solved by technology

Lack of research and development of new drugs effective against Helicobacter pylori infection

Images